Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOVON 127 BL / SAKK 37/16 in high-risk newly diagnosed Burkitt lymphoma
2023-503423-25-00Phase 3Completed
- Sponsor
- HOVON
- Start
- Jun 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of rituximab, methotrexate, ifosfamide, vincristine, cyclophosphamide and 4 more in Burkitt lymphoma (BL) (2 arms), sponsored by HOVON. Primary endpoint: 2-year progression-free survival. Started Jun 2014; status: completed.
02
Drugs
rituximabmethotrexateifosfamidevincristinecyclophosphamide
03
Conditions
Burkitt lymphoma (BL)
Beyond the preview
Go deeper on 2023-503423-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503423-25-00.